Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Baricitinib in Calcium PyrophosphAte DePosiTion DIseaSe Trial - a Proof of Concept Phase II Clinical Trial

NCT06768294 is registered in ClinicalTrials.gov with I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio as lead sponsor.

NCT NCT06768294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06768294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Baricitinib in Calcium PyrophosphAte DePosiTion DIseaSe Trial - a Proof of Concept Phase II Clinical Trial
Lead sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 31, 2025
Completion date
January 31, 2027
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

calcium pyrophosphate deposition disease, chondrocalcinosis